

BIOTIME INC
Form 8-K
September 13, 2010
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): **September 13, 2010**

BioTime, Inc.

(Exact name of registrant as specified in its charter)

California

1-12830

94-3127919

(State or other jurisdiction of (Commission File Number) (IRS Employer Identification
No.)

incorporation)

1301 Harbor Bay Parkway, Suite 100

Alameda, California 94502

(Address of principal executive offices)

(510) 521-3390

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Statements made in this Report that are not historical facts may constitute forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed. Such risks and uncertainties include but are not limited to those discussed in this report and in BioTime's other reports filed with the Securities and Exchange Commission. Words such as "expects," "may," "will," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions identify forward-looking statements.

Section 8 – Other Events

Item 8.01 – Other Events

On October 1, 2010 we will be offering for sale ten new human embryonic progenitor cell lines for research use only. The new progenitor lines were produced from embryonic stem cells using our ACTCellerate™ technology.

Human embryonic progenitor cells are intermediate in the developmental process between embryonic stem cells and fully differentiated cells. The cells may possess the ability to become a wide array of cell types with potential applications in research, drug discovery, and potential novel regenerative stem cell therapies. The cells are relatively easy to manufacture on a large scale and in a purified state, which may make it advantageous to work with these cells compared to the direct use of human embryonic stem cells

In addition to offering these new progenitor cell lines, we will also simultaneously launch corresponding cell culture media and differentiation kits. Information about the products will be available online at www.embryome.com/products.htm beginning October 1, 2010.

Section 9 – Financial Statements and Exhibits

Item 9.01 – Financial Statements and Exhibits

<u>Exhibit Number</u>	<u>Description</u>
-----------------------	--------------------

99.1	Press release dated September 13, 2010
------	--

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOTIME, INC.

Date: September 13, 2010 By: /s/ Robert W. Peabody
Senior Vice President and
Chief Operating Officer

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press release dated September 13, 2010